If you have been reading about tesamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-29. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
=== Legal status === Cipaglucosidase alfa is available in the UK, since June 2021, under the Early Access to Medicines Scheme. In December 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Pombiliti, intended for the treatment of glycogen storage disease type II (Pompe disease). The applicant for this medicinal product is Amicus Therapeutics Europe Limited. Cipaglucosidase alfa was approved for medical use in the European Union in March 2023.
(1.2) Keey et al. (2000) use a different definition of the fibre saturation point (equilibrium moisture content of wood in an environment of 99% relative humidity). Many properties of wood show considerable change as the wood is dried below the fibre saturation point, including:
expedited border control programme for low-risk travellers holding Canadian or U.S. citizenship or permanent residence. Membership requires approval by Canadian and U.S. authorities and entitles members to dedicated RFID-enabled lanes when crossing the land border. A NEXUS card can also be utilised as a travel document between the two countries and entitles passengers to priority border control facilities in Canada and Global Entry facilities in the U.S. Free and Secure Trade (FAST) is a similar programme for commercial drivers and approved importers, reducing the amount of customs checks conducted at the border and expediting the border control process. When entering the U.S. by air, holders of NEXUS cards may use Global Entry kiosks to clear border controls at participating airports SENTRI: SENTRI is a programme similar to NEXUS for U.S. and Mexican citizens that also allows members to register their cars for expedited land-border controls. Unlike NEXUS, SENTRI is administered solely by the American government and does not provide expedited controls when entering Mexico. When entering the United States by land from Canada, a NEXUS card can be used, but not the other way around. Individuals holding a NEXUS card may additionally register their cars for expedited land border controls under SENTRI. When entering the United States by air, holders of SENTRI cards may use Global Entry kiosks to clear border controls at participating airports
After several years of researching disgust, Jonathan Haidt, and others, studied its opposite; the term "elevation" was coined. Elevation is a pleasant moral emotion, triggered by witnessing virtuous acts of remarkable moral goodness and resulting in a desire to act morally and do "good". As an emotion it has a biological basis, and is sometimes characterized by a feeling of expansion in the chest or a tingling feeling on the skin.
Sources: en.wikipedia.org
Israeli defense minister Yoav Gallant met with mayors and local council heads in Nahariya, northern Israel to discuss the threat of Hezbollah to northern residents. Gallant said that if diplomacy fails, Israel will use its military to force Hezbollah north of the Litani River. On 11 December, the mayor of the southern Lebanese village of Taybeh was killed in an Israeli airstrike. Two other Hezbollah fighters were killed by Israeli airstrikes and artillery shelling in Aitaroun, and three civilians were injured. Other airstrikes were carried out by the IAF, destroying five houses and damaging 17 others. Four batches of missiles fired from Lebanon towards northern Israel were intercepted by the Iron Dome defense system, while the Islamic Resistance claimed it attacked several Israeli sites. According to Israeli media, three soldiers were injured. Hezbollah and other militias attacked nine Israeli towns and military positions. Israeli war cabinet minister and former defense minister Benny Gantz discussed security in northern Israel in a phone call with US secretary of state Antony Blinken. Gantz said he conveyed that Hezbollah's heightened aggression and attacks mean that Israel must "remove" the threat from northern Israel. Gantz's statement singled out the Lebanese state, not just Hezbollah, and called for international pressure on Lebanon to stop attacks on its southern border. The Syrian Social Nationalist Party in Lebanon announced the death of one member of their military wing, the Eagles of the Whirlwind, on 15 December.
In the US, Aducanumab is indicated for the treatment of Alzheimer's disease. In July 2021, the US Food and Drug Administration (FDA) limited the indication to people with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Aducanumab is a monoclonal IgG1 antibody that binds to the amyloid beta protein at amino acids 3–7, which is posited to result in slowing the progression of Alzheimer's disease. The mechanism is based on the amyloid hypothesis, which posits that amyloid proteins cause Alzheimer's disease, hence removing amyloid should slow the progression of the disease. How the antibody accesses the plaques is under active research. One mechanism suggests the plaques are exposed to the lumen of blood vessels and the antibody accesses the plaques from the lumen side. This assumes the plaque formed as a result of a leaky blood brain barrier and may also explain why there is hemorrhage after the plaques are removed. The most common serious adverse reactions reported are:
In May 1952, Raymond Gosling, a graduate student working under the supervision of Rosalind Franklin, took an X-ray diffraction image, labeled as "Photo 51", at high hydration levels of DNA. This photo was given to Watson and Crick by Maurice Wilkins and was critical to their obtaining the correct structure of DNA. Franklin told Crick and Watson that the backbones had to be on the outside. Before then, Linus Pauling, and Watson and Crick, had erroneous models with the chains inside and the bases pointing outwards. Franklin's identification of the space group for DNA crystals proved her correct. In February 1953, Linus Pauling and Robert Corey proposed a model for nucleic acids containing three intertwined chains, with the phosphates near the axis, and the bases on the outside. Watson and Crick completed their model, which is now accepted as the first correct model of the double helix of DNA. On 28 February 1953 Crick interrupted patrons' lunchtime at The Eagle pub in Cambridge, England to announce that he and Watson had "discovered the secret of life".
== Further reading == Robert J. Silva: Fermium, Mendelevium, Nobelium, and Lawrencium, in: Lester R. Morss, Norman M. Edelstein, Jean Fuger (Hrsg.): The Chemistry of the Actinide and Transactinide Elements, Springer, Dordrecht 2006; ISBN 1-4020-3555-1, p. 1621–1651; doi:10.1007/1-4020-3598-5_13. Seaborg, Glenn T. (ed.) (1978) Proceedings of the Symposium Commemorating the 25th Anniversary of Elements 99 and 100, 23 January 1978, Report LBL-7701 Gmelins Handbuch der anorganischen Chemie, System Nr. 71, Transurane: Teil A 1 II, p. 19–20; Teil A 2, p. 47; Teil B 1, p. 84.
3,14-Diacetyloxymorphone and its relatives including acetylmorphone do not, however, have annual production quotas published by the DEA in the Federal Register.[Citation Needed] Like all or most of the direct morphine derivatives, halogenated derivatives of these drugs and their hydromorphone and hydromorphinol analogues were synthesized in the 1930s when both the esters and the halogenated morphine derivatives were being developed, including one given as 1,2-iodo-3,6,14-triacetyl-6ɑ-14β-hydroxydihydromorphinone in a footnote to a 1948 German medical journal article about the esters of morphine. It appears that this drug was used, labelled with Iodine 129, as a tracer in animal studies, was significantly stronger than morphine, and possibly has 1- and/or 2- fluoro, chloro, and bromo analogues.[Citation Needed] 3,6-Diacetyloxymorphone is a third acetylated oxymorphone derivative, the oxymorphone analogue of acetylmorphone and expected to be intermediate in strength betwixt the two aforementioned drugs. Another is 3-acetyloxymorphone.
Sources: en.wikipedia.org
Ice-nine is a fictional material that appears in Kurt Vonnegut's 1963 novel Cat's Cradle. Ice-nine is described as a polymorph of ice which instead of melting at 0°C (32°F) melts at 45.8°C (114.4°F). When ice-nine comes into contact with liquid water below 45.8°C, it acts as a seed crystal and causes the solidification of the entire body of water, which quickly crystallizes as more ice-nine. As humans are 55-60% water, ice-nine kills nearly instantly when ingested or brought into contact with soft tissues exposed to the bloodstream, such as the eyes or lips. In the story, ice-nine is invented by Dr. Felix Hoenikker while working on the Manhattan Project in response to a suggestion from a Marine general, who complained about soldiers having to deal with mud on the battlefield. The project is abandoned when it becomes clear that any quantity of the substance would have the power to destroy all life on Earth. In the novel's climax, the Earth's oceans are accidentally frozen solid by ice-nine, prompting a doomsday scenario. Vonnegut encountered the idea of ice-nine while working at General Electric. He attributes the idea of ice-nine to his brother Bernard Vonnegut, who was researching the formation of ice crystals in the atmosphere. A later account of the events attributes the idea to the chemist Irving Langmuir, who devised the concept while helping H.G. Wells conceive ideas for stories. Vonnegut decided to adapt the idea into a story after Langmuir's death in 1957.
=== Pharmacokinetics === The bioavailability of methylergometrine is 60% via oral administration and 78% by intramuscular injection. It is metabolized in the liver, with extensive first-pass metabolism. The elimination half-life of the drug is 3.4 hours. It is eliminated mainly via metabolism and then excreted.
== Channel blockers == P-type calcium channel blockers act to impede the flow of calcium. The blocking of calcium currents may cause the organism to experience impaired functioning and viability. These effects can lead to various diseases which are described in more detail in the section below. The pore of P-type calcium channels are sensitive to compounds that can be divided into three groups:
=== United States === In 1993, the product was approved for use in the US by the FDA, and its use began in 1994. The product is now sold in all 50 states. The FDA stated that food products made from rBST-treated cows are safe for human consumption, and no statistically significant difference exists between milk derived from rBST-treated and untreated cows. The FDA found BST to be biologically inactive when consumed by humans and found no biological distinction between rBST and BST. In 1990, an independent panel convened by the National Institute of Health supported the FDA opinion that milk and meat from cows supplemented with rBST is safe for human consumption.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.